TRAW Traws Pharma, Inc.

Nasdaq www.trawspharma.com


$ 2.19 $ 0.40 (22.6 %)    

Friday, 14-Nov-2025 15:54:24 EST
QQQ $ 608.45 $ 0.46 (0.08 %)
DIA $ 471.65 $ -2.94 (-0.62 %)
SPY $ 671.62 $ -0.11 (-0.02 %)
TLT $ 88.93 $ -0.51 (-0.57 %)
GLD $ 375.82 $ -6.91 (-1.8 %)
$ 2.17
$ 1.75
$ 2.18 x 4,100
$ 2.21 x 1,000
$ 1.82 - $ 2.77
$ 0.97 - $ 19.44
8,122,187
na
17.34M
$ 1.15
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 11-13-2025 09-30-2025 10-Q
2 08-14-2025 06-30-2025 10-Q
3 05-15-2025 03-31-2025 10-Q
4 03-31-2025 12-31-2024 10-K
5 11-14-2024 09-30-2024 10-Q
6 08-14-2024 06-30-2024 10-Q
7 05-15-2024 03-31-2024 10-Q
8 04-01-2024 12-31-2023 10-K
9 11-14-2023 09-30-2023 10-Q
10 08-14-2023 06-30-2023 10-Q
11 05-15-2023 03-31-2023 10-Q
12 03-30-2023 12-31-2022 10-K
13 11-14-2022 09-30-2022 10-Q
14 08-15-2022 06-30-2022 10-Q
15 05-13-2022 03-31-2022 10-Q
16 03-21-2022 12-31-2021 10-K
17 11-15-2021 09-30-2021 10-Q
18 08-16-2021 06-30-2021 10-Q
19 05-17-2021 03-31-2021 10-Q
20 03-18-2021 12-31-2020 10-K
21 11-16-2020 09-30-2020 10-Q
22 08-12-2020 06-30-2020 10-Q
23 05-15-2020 03-31-2020 10-Q
24 03-27-2020 12-31-2019 10-K
25 11-12-2019 09-30-2019 10-Q
26 08-14-2019 06-30-2019 10-Q
27 05-15-2019 03-31-2019 10-Q
28 04-01-2019 12-31-2018 10-K
29 11-14-2018 09-30-2018 10-Q
30 08-14-2018 06-30-2018 10-Q
31 05-15-2018 03-31-2018 10-Q
32 03-16-2018 12-31-2017 10-K
33 11-09-2017 09-30-2017 10-Q
34 08-14-2017 06-30-2017 10-Q
35 05-15-2017 03-31-2017 10-Q
36 03-29-2017 12-31-2016 10-K
37 11-14-2016 09-30-2016 10-Q
38 08-15-2016 06-30-2016 10-Q
39 05-11-2016 03-31-2016 10-Q
40 03-28-2016 12-31-2015 10-K
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

Core News & Articles

-SEC Filing

Core News & Articles

Non-inferiority trial to assess safety and efficacy, including rates of disease rebound and incidence of Long COVID development...

Core News & Articles

Traws Pharma (NASDAQ:TRAW) reported quarterly losses of $(0.11) per share. This is a 99.46 percent increase over losses of $(20...

Core News & Articles

Phase 2 protocol submitted to HREC to evaluate tivoxavir marboxil (TXM) in a combined seasonal and bird flu study in the Southe...

Core News & Articles

Traws Pharma, Inc. (NASDAQ:TRAW) ("Traws Pharma", "Traws" or "the Company"), a clinical-stage biopharma...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION